Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Siga, ViroPharma deal

SIGA agreed to purchase from VPHM certain antiviral programs targeting potential

Read the full 112 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE